Nurix Therapeutics, Inc.

NASDAQ:NRIX

Biotechnology

Healthcare
$14.10 +0.85%

+$0.15 today

Market cap
$1.54B
Beta
1.87
P/E (TTM)
-6.4
EPS (TTM)
-$2.68
52W Low $8.20High $22.50

Volume 2.79M

Average 1.74M

NRIX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Nurix Therapeutics, Inc.NASDAQ: NRIX

Weighted Avg Shares · Q3 FY2026 · quarter ended Aug 2026

Weighted avg shares growth accelerates

Q3 FY2026 weighted avg shares of 111.56M shares rose 32.6% year over year, ahead of the +29.6% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.4% from the prior quarter. Over 3 fiscal years it compounded at +21.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +32.6% holds above the trailing-twelve-month pace of +29.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterAug 2026
111.56M+0.4% QoQ
Last fiscal yearNov 2025
86.67M+29.1% YoY
LTMAug 2026
106.95M+29.6% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.6%——
1 year+29.1%——
3-year CAGR+21.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
86.67M USD
Year-over-year change
+29.1%
4-year CAGR
+19.2%

Weighted Avg Shares vs competitors

How NRIX compares with its peers on the latest reported figures

  • NRIX's LTM Aug 2026 weighted avg shares of 106.95M shares is the 3rd highest of the 8 companies compared; the peer median is 91.85M shares.
  • Its year-over-year change of +29.6% is the 3rd highest of 8, against a peer median of +10.9%.
  • Over three fiscal years its annual growth of +21.3% compares with a peer median of +12.5%.
NRIX Competitors Peer median
Weighted Avg Shares for NRIX and competitors
Company Period LTM YoY 3-year CAGR
RVMDRevolution Medicines, Inc.LTM Jun 2026197.09M +10.9%+33.1%
TNGXTango Therapeutics, Inc.LTM Sep 2026145.89M +32.5%+9.8%
NRIXNurix Therapeutics, Inc.LTM Aug 2026106.95M +29.6%+21.3%
CCCCC4 Therapeutics, Inc.LTM Mar 202696.61M +38.1%+19.3%
KYMRKymera Therapeutics, Inc.LTM Jun 202691.85M +16.0%+16.1%
KURAKura Oncology, Inc.LTM Mar 202687.97M +1.1%+9.4%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 202686.55M +1.2%+12.5%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202618.08M +2.4%+1.4%
Peer median (excluding NRIX) 91.85M+10.9%+12.5%

Competitors are the stored peer set for NRIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Nov 2021
FY2022
Nov 2022
FY2023
Nov 2023
FY2024
Nov 2024
FY2025
Nov 2025
Revenue29.75M38.63M76.99M54.55M83.98M
Cost of Revenue116.43M184.5M189.15M221.63M18.86M
Gross Profit(86.68M)(145.87M)(112.16M)(167.08M)65.12M
Gross Margin-291.4%-377.6%-145.7%-306.3%77.5%
Research & Development116.43M184.5M189.15M221.63M308.16M
Selling, General & Admin31.2M38M42.9M45.94M52.74M
Operating Expenses31.2M38M42.9M45.94M350.79M
Depreciation & Amortization6.08M10.81M13.65M16.43M18.86M
EBITDA(110.98M)(169.55M)(130.29M)(176.87M)(244.84M)
EBITDA Margin-373.0%-438.9%-169.2%-324.2%-291.5%
Operating Income(117.89M)(183.87M)(155.06M)(213.03M)(285.67M)
Operating Margin-396.3%-476.0%-201.4%-390.5%-340.2%
Interest Income823K3.51M11.12M19.73M21.97M
Interest Expense00000
Other Income / Expenses823K3.51M11.12M19.73M21.97M
Income Before Tax(117.06M)(180.36M)(143.95M)(193.3M)(263.7M)
Pre-Tax Margin-393.5%-466.9%-187.0%-354.4%-314.0%
Income Tax Expense131K00270K760K
Net Income(117.19M)(180.36M)(143.95M)(193.57M)(264.46M)
Net Margin-393.9%-466.9%-187.0%-354.9%-314.9%
EPS (Basic)(2.73)(3.71)(2.65)(2.88)(3.05)
EPS (Diluted)(2.73)(3.71)(2.65)(2.88)(3.05)
Weighted Avg Shares42.9M48.61M54.34M67.12M86.67M
Weighted Avg Shares (Diluted)42.9M48.61M54.34M67.12M86.67M

Nurix Therapeutics, Inc.

NASDAQ:NRIX

Intrinsic Alpha fair value

Locked

Current Price

$14.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.